中航電子(600372.SH):使用可轉債募集資金向子公司增資4992萬元
格隆匯6月2日丨中航電子(600372.SH)公佈,2020年6月2日,公司召開第六屆董事會2020年度第四次會議(臨時),審議通過《關於審議使用可轉債募集資金向子公司進行第七期增資的議案》,同意公司以現金增資形式向部分募投項目實施主體進行第七期增資,增資總額4992萬元,增資來源為公司本次可轉債發行所募集資金。
本次增資有利於提高募集資金使用效率,保證募投項目順利實施,增強公司持續盈利的能力,提升公司綜合競爭力。本次增資不存在改變或變相改變募集資金用途的情形,符合公司披露的本次可轉債發行方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.